Organon

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Retrieved on: 
木曜日, 5月 9, 2024
Cream, CVR, Sale, FDA, BRAF V600, Organon, NDA, Food, Compugen, Department of Defence, Economics, Female, BRAF, PDUFA, Blue Owl Capital, Patient, Bayer, Acquisition, Share repurchase, Food and Drug Administration, Defense, Pharmaceutical industry

EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Key Points: 
  • Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib);
    EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.
  • XOMA receives 100 percent of the DSUVIA® economics until a threshold is achieved; thereafter, XOMA retains the 15 percent royalty associated with DSUVIA® commercial sales.
  • The 75 percent royalties from Department of Defense purchases and remaining milestone payments will be shared equally between XOMA and Talphera.
  • Dosed first patient in its Phase 3 trial of RZ358; XOMA earned a $5.0 million milestone associated with the event.

Medicines360 Appoints Erica Rogers to Board of Directors

Retrieved on: 
水曜日, 4月 10, 2024
Medtech, Organon, Woman, Engineering, IPO, Science, Boston Scientific, SAN, Pharmaceutical industry

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024.
  • Ms. Rogers, an accomplished innovator and entrepreneur, brings over 30 years of experience leading high-growth health technology companies to Medicines360.
  • “Medicines360 has demonstrated considerable impact, helping over 1.5 million women to date, driven by its mission to improve equitable health outcomes,” said Ms. Rogers.
  • “We are thrilled to welcome Erica Rogers to our Board of Directors.

Syniti Starts 2024 with a Bang: Data First Strategy, AI and Turnaround Projects Deliver Record Revenue

Retrieved on: 
火曜日, 4月 23, 2024
Erg, Organization, Organon, ARR, Woman, AI, Research, Conference, Growth, Women's History Month, HFS, Engineering, Data, Trust, Data management, SAP, Black History Month, Informal economy, Video game

BOSTON, April 23, 2024 /PRNewswire/ -- Syniti, a global leader in enterprise data management, today announced record-breaking first quarter 2024 results, setting the stage for a strong year. The company reports its highest revenue in company history as customers continue to turn to Syniti and its Data First strategy to drive greater success in their critical business transformation projects. The company also saw significant increases in both software revenue and annual recurring revenue (ARR) when compared to the first quarter of 2023. Services bookings were the highest recorded first quarter bookings ever, up 65% over Q1 2023.

Key Points: 
  • The company reports its highest revenue in company history as customers continue to turn to Syniti and its Data First strategy to drive greater success in their critical business transformation projects.
  • The company also saw significant increases in both software revenue and annual recurring revenue (ARR) when compared to the first quarter of 2023.
  • Whether organizations are modernizing systems or trying to make the most of AI, they must start with clean, quality data to achieve their desired goals.
  • Syniti's Data First approach prioritizes data quality before the project begins, converging its technology, business data expertise and methodology for greater understanding of data in context and faster time to value.

Inception Fertility™ 2024 Annual Physician Summit: A Celebration of Collaboration, Patient Dedication, and Advancements in Fertility Research

Retrieved on: 
木曜日, 3月 14, 2024
Diamond, Health, Prelude, Organon, Learning, Merck Serono, Ferring Pharmaceuticals, Physician, Patient, Mental health, Patient experience, Reproductive medicine, Fertility, Labcorp, Inception, The Cooper Companies, Summit, Family, Parent, Nursing

HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.

Key Points: 
  • Global fertility leader's annual summit brings together physicians, team members across Inception's expansive family of brands
    HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility ™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.
  • This included two full days of learning, team building, collaborating, and the field of reproductive medicine.
  • Panel sessions covered topics related to mental health in fertility care, groundbreaking research studies, and using technology to drive the patient and employee experience, among others.
  • The 2024 Patient Experience Awards included the Patient Experience Outstanding Practice Award, Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, and Patient Experience Tenet Leaders Awards.

Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
土曜日, 3月 9, 2024
EMA, Week, Psoriasis, Committee, SB5, Political moderate, Ustekinumab, Organon, FDA, Food, Samsung, BLA, Trial of the century, AAD, Safety, CHMP, Pharmacokinetics, Abstract, Biologics license application, American Academy, Novartis, Interchangeability

“We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.

Key Points: 
  • “We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
  • The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and prefilled autoinjector of HADLIMA was approved in August 2022.
  • The study showed that efficacy, safety, and immunogenicity between the three arms were comparable up to Week 52.
  • Details of the Samsung Bioepis’ abstracts are as follows:
    Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
火曜日, 2月 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Retrieved on: 
月曜日, 12月 18, 2023
Health, Other Consumer, Consumer, Women, Other Health, Pharmaceutical, Biotechnology, Galcanezumab, Sale, Norton Lilly International, Vomiting, Woman, Migraine, NYSE, Headache, Disease, Patient, Light, OGN, Eli Lilly and Company, Nausea, Disability, Central nervous system, CGRP, Education, Pharmaceutical industry, Lilly, Organon

RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Key Points: 
  • RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
  • “This commercialization agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our Established Brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine,” said Kevin Ali, Organon CEO.
  • “We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”
    Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe.
  • Total consideration to be paid to Lilly includes an upfront payment of $50 million and sales-based milestone payments.

MATTER opens applications for accelerator focused on reducing maternal mortality in the U.S.

Retrieved on: 
火曜日, 12月 12, 2023
Pharmaceutical, Health Technology, Health Insurance, Research, Parenting, Healthcare Reform, Public Policy, Government, Hospitals, Baby, Maternity, Fitness & Nutrition, Clinical Trials, University, Education, Biotechnology, Women, Professional Services, Health, Practice Management, Vitamins, Supplements, General Health, Science, Consumer, Social Services, Other Health, Health Care Service Corporation, Infant, Parkview Health, Incidence, Prenatal care, BayCare Ballpark, Mortality, Pregnancy, Mentorship, Death, Labs, HCSC, Mother, Risk, Organon, Dietary supplement

MATTER , the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs , an accelerator focused on women’s health.

Key Points: 
  • MATTER , the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs , an accelerator focused on women’s health.
  • This year’s program focuses on preventing maternal mortality in the U.S. before, during and after birth and receives support from Health Care Service Corporation , Laerdal Million Lives Fund , BayCare , Parkview Health , University of Chicago Medicine , Organon and Stryker .
  • While all ages and races saw an increase in maternal mortality in 2021, many inequities still exist due to a variety of factors, including but not limited to access to quality care, socioeconomic status, race and education level.
  • The second cohort of the 51 Labs accelerator will address the question:
    How can we prevent maternal mortality in the U.S. before, during and after birth?

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
火曜日, 11月 21, 2023
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, EST, OGN, NYSE, Conference, Piper Sandler Companies, Pharmaceutical industry, Organon

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Retrieved on: 
木曜日, 11月 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pfizer, Integra, Chemistry, MTX, Kyowa Kirin, University College Utrecht, Patient, Multimedia, Isoti, FDA, Alliance Manchester Business School, IPO, MBA, University, Partnership, Integra LifeSciences, Fast Track, Organon, Management

Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Key Points: 
  • Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
    Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
    Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
  • Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
  • Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.